C4 Therapeutics

CCCCPhase 2

C4 Therapeutics is dedicated to transforming patient lives by developing a new generation of medicines based on targeted protein degradation (TPD), a therapeutic modality that offers advantages over traditional inhibition. The company's core TORPEDO® platform integrates novel E3 ligase binders and chemical libraries to create selective protein degraders. With key partnerships with Roche, Biogen, and Merck KGaA, and a clinical-stage pipeline led by Cemsidomide, C4T is positioned at the forefront of the TPD field, aiming to address significant unmet needs in oncology and beyond.

Market Cap

$263.5M

Focus

Small Molecules

CCCC · Stock Price

USD 2.7022.14 (-89.13%)

Historical price data

AI Company Overview

Technology Platform

The TORPEDO® platform is an integrated drug discovery engine for targeted protein degradation (TPD), designed to create novel small-molecule degraders by leveraging proprietary E3 ligase binders and chemical libraries to selectively eliminate disease-causing proteins.

Pipeline Snapshot

5 drugs in pipeline

Drug	Indication	Stage
Cemsidomide + Dexamethasone	Multiple Myeloma	Phase 2
Cemsidomide + Elranatamab	Multiple Myeloma (MM)	Phase 1
CFT1946 + Trametinib + Cetuximab	Solid Tumors	Phase 1
CFT8634	Synovial Sarcoma	Phase 1
cemsidomide + Dexamethasone Oral	Multiple Myeloma	Phase 1

Opportunities

Significant growth opportunity lies in validating the TORPEDO® platform through clinical success, which would unlock value across its internal pipeline and enhance its partnership offerings.

Expansion into new therapeutic areas beyond oncology, potentially leveraging partner expertise, represents another major avenue for growth.

Risk Factors

Key risks include clinical trial failures for lead assets Cemsidomide and CFT8919, high cash burn requiring future dilutive financings, and intense competition from other TPD companies and large pharma with similar platforms.

The novel scientific approach carries inherent biological and development uncertainty.

Competitive Landscape

C4T competes with other clinical-stage TPD leaders like Arvinas, Kymera, and Nurix, as well as internal efforts at large pharma. Its differentiation is based on the TORPEDO® platform's focus on novel E3 ligases and its validated strategic partnerships with Roche, Biogen, and Merck KGaA.